[go: up one dir, main page]

EE04452B1 - Farmatseutiliselt aktiivne morfolinool ja selle kasutamine - Google Patents

Farmatseutiliselt aktiivne morfolinool ja selle kasutamine

Info

Publication number
EE04452B1
EE04452B1 EEP200000438A EEP200000438A EE04452B1 EE 04452 B1 EE04452 B1 EE 04452B1 EE P200000438 A EEP200000438 A EE P200000438A EE P200000438 A EEP200000438 A EE P200000438A EE 04452 B1 EE04452 B1 EE 04452B1
Authority
EE
Estonia
Prior art keywords
pharmaceutically active
morpholinol
active morpholinol
pharmaceutically
active
Prior art date
Application number
EEP200000438A
Other languages
English (en)
Estonian (et)
Inventor
Frederick Morgan Phillip
Lee Musso David
Joseph Partridge John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000438A publication Critical patent/EE200000438A/xx
Publication of EE04452B1 publication Critical patent/EE04452B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000438A 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine EE04452B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (2)

Publication Number Publication Date
EE200000438A EE200000438A (et) 2001-12-17
EE04452B1 true EE04452B1 (et) 2005-04-15

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000438A EE04452B1 (et) 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine

Country Status (30)

Country Link
US (2) US6274579B1 (xx)
EP (2) EP1047428B1 (xx)
JP (1) JP2002501025A (xx)
KR (1) KR100568063B1 (xx)
CN (2) CN1203858C (xx)
AP (1) AP1229A (xx)
AT (1) ATE365042T1 (xx)
AU (1) AU755536B2 (xx)
BR (1) BR9907203A (xx)
CA (1) CA2318268A1 (xx)
CY (1) CY1106828T1 (xx)
DE (1) DE69936335T2 (xx)
DK (1) DK1047428T3 (xx)
EA (1) EA002410B1 (xx)
EE (1) EE04452B1 (xx)
ES (1) ES2288012T3 (xx)
HR (2) HRP20051024A2 (xx)
HU (1) HUP0100900A3 (xx)
ID (1) ID26334A (xx)
IL (2) IL161942A0 (xx)
IS (1) IS2494B (xx)
NO (2) NO326878B1 (xx)
NZ (3) NZ520349A (xx)
PL (1) PL193622B1 (xx)
PT (1) PT1047428E (xx)
SG (1) SG115489A1 (xx)
SK (1) SK10912000A3 (xx)
TR (1) TR200002126T2 (xx)
WO (1) WO1999037305A1 (xx)
YU (1) YU67102A (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
CA2318921A1 (en) * 1998-01-29 1999-08-05 John R. Mccullough Pharmacological uses of optically pure (+)-bupropion
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
EP1220673A2 (en) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (en) * 2000-12-21 2008-10-21 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
DE60324685D1 (de) * 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
DE602004012403T2 (de) * 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
JP2007509855A (ja) * 2003-10-27 2007-04-19 スミスクライン ビーチャム コーポレーション （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するためのジアステレオマー動的速度論分割プロセス
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007079470A2 (en) 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2089005B1 (en) 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
CA2800219C (en) * 2010-05-21 2019-03-12 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
JP2002501025A (ja) 2002-01-15
AP2000001869A0 (en) 2000-09-30
DK1047428T3 (da) 2007-10-08
CY1106828T1 (el) 2012-05-23
EE200000438A (et) 2001-12-17
CN1255389C (zh) 2006-05-10
AU2328099A (en) 1999-08-09
CN1294513A (zh) 2001-05-09
CN1528753A (zh) 2004-09-15
WO1999037305A1 (en) 1999-07-29
HRP20000494A2 (en) 2000-12-31
IS5568A (is) 2000-07-20
BR9907203A (pt) 2000-10-17
PL342012A1 (en) 2001-05-07
CA2318268A1 (en) 1999-07-29
NO20003721D0 (no) 2000-07-20
ES2288012T3 (es) 2007-12-16
EP1047428A4 (en) 2001-12-19
HUP0100900A2 (hu) 2002-05-29
AP1229A (en) 2003-12-04
SG115489A1 (en) 2005-10-28
IL137346A0 (en) 2001-07-24
ID26334A (id) 2000-12-14
DE69936335T2 (de) 2008-02-28
HRP20000494B1 (en) 2009-02-28
IS2494B (is) 2009-02-15
PT1047428E (pt) 2007-09-07
US6274579B1 (en) 2001-08-14
CN1203858C (zh) 2005-06-01
EP1829544A1 (en) 2007-09-05
KR100568063B1 (ko) 2006-04-07
HUP0100900A3 (en) 2002-08-28
SK10912000A3 (sk) 2001-04-09
KR20010034285A (ko) 2001-04-25
NO20083529L (no) 2000-09-19
IL161942A0 (en) 2005-11-20
NO326878B1 (no) 2009-03-09
HRP20051024A2 (hr) 2006-04-30
PL193622B1 (pl) 2007-02-28
YU67102A (sh) 2004-12-31
EP1047428B1 (en) 2007-06-20
ATE365042T1 (de) 2007-07-15
DE69936335D1 (de) 2007-08-02
AU755536B2 (en) 2002-12-12
EA002410B1 (ru) 2002-04-25
TR200002126T2 (tr) 2000-12-21
NO20003721L (no) 2000-09-19
US6391875B2 (en) 2002-05-21
EA200000691A1 (ru) 2001-04-23
NZ520349A (en) 2004-02-27
NZ505809A (en) 2002-09-27
NZ529316A (en) 2004-05-28
EP1047428A1 (en) 2000-11-02
US20020019396A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EE200200341A (et) Asendatud oksasolidinoonid ja nende kasutamine
EE05210B1 (et) Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis
DE69918074D1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
EE200200484A (et) Väikeseannuseline entekaviiripreparaat ja selle kasutamine
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
ID26340A (id) Kapsul ganda dengan penggunaan bahan-bahan aktif dalam berbagai macam pengobatan
ID22957A (id) Senyawa dan penggunaannya
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
ID22889A (id) Komposisi kopolimer etilena dan penggunaannya
NO20012915D0 (no) Ny farmasöytisk formulering
NO994438D0 (no) Terapeutisk aktive diarylpropylaminer samt fremstilling og anvendelse derav
ID26599A (id) Turunan triazola dan imidazola
ID24196A (id) Komposisi dan penggunaan
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
PT1274308E (pt) Combinacoes de substancias activas com propriedades insecticidas e acaricidas
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
DE59814201D1 (de) Polybenzoxazol- und Polybenzothiazol-Vorstufen
EE03667B1 (et) Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis
EE200100051A (et) Vastavast (-)-stereoisomeerist põhiliselt vaba (+)-nortsisapriidi või selle farmatseutiliselt vastuvõetava soola kasutamine ja farmatseutiline kompositsioon
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
DE59902159D1 (de) Aktiver mikromischer
EE200200096A (et) IREN-valk, selle valmistamine ja kasutamine
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
IT1291823B1 (it) Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130120